Emerging Peptides & Frontier Compounds: Evidence-Ranked Guide

Q: What are senolytic peptides?

Senolytic peptides (like FOXO4-DRI) target senescent cells — cells that have stopped dividing but don't die, contributing to aging and inflammation. FOXO4-DRI has strong animal data but very early human evidence (★★☆☆☆). This is an emerging area of longevity research.

Q: What is the difference between retatrutide and tirzepatide?

Tirzepatide is a dual agonist (GIP + GLP-1) — FDA-approved. Retatrutide is a triple agonist (GIP + GLP-1 + glucagon) — in Phase 3 trials. The additional glucagon receptor activation in retatrutide increases energy expenditure (calorie burning) on top of appetite suppression.

This category covers compounds at the frontier of peptide research, triple-agonist drugs in Phase 3 trials, senolytic peptides targeting cellular aging, novel Wnt pathway modulators, and compounds that don't fit neatly into other categories. These are the peptides to watch as clinical trials progress through 2026 and beyond. This reference profiles 27 peptides and compounds in the specialty and emerging category. Each is ranked by scientific evidence strength, with clinical trial status and FDA status clearly marked.

How to Read Evidence Ratings

★★★★★

Strong Clinical Evidence

Multiple high-quality human clinical studies consistently support the effect.

★★★★☆

Good Human Evidence

Meaningful human data, but may be limited by study size or design.

★★★☆☆

Preliminary Human Evidence

Some human research exists, but early, limited, or mixed.

★★☆☆☆

Primarily Preclinical

Evidence from animal or lab studies. Limited or no human data.

★☆☆☆☆

Mechanistic Only

Plausible mechanism, but little direct evidence for the claimed outcome.

★★★★☆ / ★★☆☆☆

Split Rating

Different evidence by use (topical vs. injectable, approved vs. off-label).

Important: Star ratings measure evidence strength, not safety.

Peptide Comparison Table

Every compound in this category, ranked by evidence strength.

Peptide	FDA Status	Evidence	Key Note
Semaglutide (Ozempic)	FDA-Approved	★★★★★	See Guide 1
Tirzepatide (Mounjaro)	FDA-Approved	★★★★★	See Guide 1
Retatrutide (LY3437943)	Phase 3 Trials	★★★★☆	Strong Phase 2 human data; Phase 3 in progress
GHK-Cu (Copper Peptide)	Cosmetic / Research	★★★★☆	Split rating; see Guide 7
Bimagrumab (LY3002813)	Phase 2 Completed	★★★☆☆	Phase II human data on body composition
SM04554 (Lorecivivint)	Phase 2 Completed	★★★☆☆	Phase II human trials for joint/Wnt pathway
Pemvidutide (AZD9550)	Phase 2	★★★☆☆	Phase II human data
UBX1325	Phase 2	★★★☆☆	Phase II human trials (senolytic/ophthalmology)
MK-677 (Ibutamoren)	Research	★★★☆☆	Multiple human studies; see Guide 1
Thymosin Alpha-1	Approved in 35+ countries / Research in US	★★★☆☆	See other guides
GHRP-2	Research	★★★☆☆	See other guides
ACE-031	Research (halted)	★★★☆☆	Phase II completed; see Guide 2
ACE-083	Research (discontinued)	★★★☆☆	Phase II completed; see Guide 2
BPC-157	Research	★★☆☆☆	See Guide 2
TB-500 (Thymosin Beta-4)	Research	★★☆☆☆	See Guide 2
Ipamorelin	Research	★★☆☆☆	See other guides
Mod GRF 1-29 (CJC without DAC)	Research	★★☆☆☆	See Guide 1 (CJC-1295 No DAC)
GHRP-6	Research	★★☆☆☆	See other guides
CJC-1295 DAC	Research	★★☆☆☆	See other guides
IGF-1 LR3	Research	★★☆☆☆	See other guides
AOD-9604	Research	★★☆☆☆	See Guide 1
FOXO4-DRI	Research (senolytic)	★★☆☆☆	Animal senolytic data strong; very early human data
PNC-27	Research	★★☆☆☆	Primarily preclinical
UBT251	Phase 1/2	★★☆☆☆	Very early human data
WAY-316606	Research	★☆☆☆☆	Primarily mechanistic; Wnt activator research tool
WNT-related peptides	Research (experimental)	★☆☆☆☆	Primarily mechanistic/experimental
PTD-DMB	Research	★☆☆☆☆	Wnt pathway research; no human trial data

Top Compounds

Bimagrumab (★★★☆☆), Phase 2 Completed

A monoclonal antibody targeting activin type II receptors, studied for changing body composition (replacing fat with muscle). Phase II completed with positive human data.

SM04554 / Lorecivivint (★★★☆☆), Phase 2 Completed

A Wnt pathway modulator studied for joint repair and osteoarthritis. Phase II human trials completed. An interesting non-traditional approach to tissue repair.

FOXO4-DRI (★★☆☆☆), Research (Senolytic)

A senolytic peptide that targets senescent cells (a hallmark of aging). Animal data is strong; human data is very early. One of the most-watched frontier compounds in longevity research.

Pemvidutide (★★★☆☆), Phase 2

A dual GLP-1/glucagon agonist in Phase II trials for obesity and liver disease. Represents the next wave of incretin therapy beyond semaglutide and tirzepatide.

Frequently Asked Questions

What is retatrutide and when will it be approved?

Retatrutide is a triple GIP/GLP-1/glucagon agonist in Phase 3 trials (TRIUMPH program). Phase 2 data showed ~24% body-weight loss. An FDA decision is anticipated around 2026–2027. It is not currently approved or available outside clinical trials.

What are senolytic peptides?

Senolytic peptides (like FOXO4-DRI) target senescent cells, cells that have stopped dividing but don't die, contributing to aging and inflammation. FOXO4-DRI has strong animal data but very early human evidence (★★☆☆☆). This is an emerging area of longevity research.

What is bimagrumab and what does it do?

Bimagrumab is a monoclonal antibody that blocks activin type II receptors, shifting body composition from fat to muscle. Phase II human trials completed with positive data (★★★☆☆). It is not FDA-approved.

What is the difference between retatrutide and tirzepatide?

Tirzepatide is a dual agonist (GIP + GLP-1), FDA-approved. Retatrutide is a triple agonist (GIP + GLP-1 + glucagon), in Phase 3 trials. The additional glucagon receptor activation in retatrutide increases energy expenditure (calorie burning) on top of appetite suppression.

Are emerging peptides available for use?

Most emerging peptides are in clinical trials and not available outside those trials. Compounds in Phase 1/2 (UBT251, WAY-316606, WNT-related peptides) have very early or no human data. Do not use research-stage compounds without clinical supervision.

Get the Complete Guide

Every compound in this category, fully profiled with mechanisms, evidence ratings, FDA status, and research citations.

Get the Specialty & Emerging Guide, $19.99 →

One-time purchase. Instant download. No subscription.